PRIYAL AMIN: Open Payments
NPI 1366177479 · BEAUMONT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,384 in 52 payments from 28 companies in 2025. Trend: 2023 $20 · 2024 $630 · 2025 $1,384
Food & beverage: $1,209Education: $175
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $195 |
| Celgene Corporation | 4 | $106 |
| Novartis Pharmaceuticals Corporation | 4 | $88 |
| Janssen Biotech, Inc. | 3 | $83 |
| Agios Pharmaceuticals, Inc. | 3 | $76 |
| SOBI, INC | 3 | $67 |
| ABBVIE INC. | 3 | $65 |
| Lilly USA, LLC | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $59 |
Products named: PYRUKYND, REBLOZYL, VERZENIO, TECVAYLI, LIBTAYO, Nubeqa, SCEMBLIX, NERLYNX.
Industry payments across CA — which companies pay providers there.
